I lyset af de identificerede risici, bør coumatetralyl kun optages i bilag I for en femårsperiode, og der bør foretages en sammenlignende risikovurdering i overensstemmelse med artikel 10, stk. 5, nr. i), andet led, i direktiv 98/8/EF, inden dets optagelse i bilag I forlænges.
In view of the identified risks, coumatetralyl should be included in Annex I for five years only and should be made subject to a comparative risk assessment in accordance with the second subparagraph of Article 10(5)(i) of Directive 98/8/EC before its inclusion in Annex I is renewed.